SELLAS Announces First Patient Dosed iI Phase 2a Clinical Trial Of GFH009 In Acute Myeloid Leukemia
Portfolio Pulse from Happy Mohamed
SELLAS Life Sciences has dosed the first patient in a Phase 2a clinical trial of its CDK9 inhibitor, GFH009, in combination with venetoclax and azacitidine for relapsed/refractory acute myeloid leukemia. Topline data is expected in Q4 2023.
June 22, 2023 | 12:49 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
SELLAS Life Sciences has initiated a Phase 2a trial of GFH009 for relapsed/refractory acute myeloid leukemia, which could potentially enhance the company's value if successful.
The initiation of the Phase 2a trial for GFH009 is a significant milestone for SELLAS Life Sciences, as it could potentially lead to a new treatment option for relapsed/refractory acute myeloid leukemia patients. If the trial is successful, it could enhance the company's value and positively impact its stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100